Vanessa Zann and Chris Roe: Q&A with Pharmaceutical Technology on Successfully Accelerating Formulation Strategies
Accelerated formulation strategies can aid with cost and time-efficiencies in drug development. However, there are key challenges of which developers must be aware to ensure success. To discuss the primary hurdles to accelerated formulation strategies and best practices for developers.
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant Topline results expected Q3 2022
Matt Paterson featured in Pharma Manufacturing - 2022 Pharma Predictions
Quotient's Vice President of Corporate Strategy has been featured in the 2022 Pharma Predictions article on Pharma Manufacturing.
Pharmaceutical Technology interview with Paul Quigley, Head of Production, Drug Substance on timeline acceleration with drug substance and drug product
Paul Quigley, Head of Production, Drug Substance at Quotient Sciences, was featured in a interview with Pharmaceutical Technology regarding the acceleration of development timelines between drug substance and drug product.
Clinical Trials Arena Interview with Stuart McDougall, VP of Bioanalytical Services on bioanalytical and pharmacokinetics (PK) strategies
Quotient's VP of Bioanalytical Services, Stuart McDougall was featured in an interview with Clinical Trials Area discussing the Bioanalytical and Pharmacokinetics (PK) strategies at Quotient, and how we reduce risk and delay within the drug development process.
Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences
Oxilio signed an exclusive global licensing agreement with TRx Biosciences on 20th October 2021 for the use of their platformtechnology to support the development of Oxilio’s formulation, OXL001. Oxilio has since progressed the product and nowsigned a significant service contract with Quotient Sciences, a drug development and manufacturing accelerator, to support the formulation development and preparation of clinical trials for OXL001.